Market Research Logo

Global Ankylosing Spondylitis Market 2015-2019

Global Ankylosing Spondylitis Market 2015-2019

About Ankylosing Spondylitis

Ankylosing spondylitis is a subtype of spondylarthropathy. The primary symptoms of the disease are inflammatory spinal pain with subsequent limitation of spine mobility and chest expansion. Ankylosing spondylitis can be diagnosed using clinical signs, radiological signs (sacroiliitis) and the presence of HLA-B27 antigen. According to the NIH and NIAMS, ankylosing spondylitis is a type of arthritis, which affects the joints in the vertebral column severely. It is a progressive inflammatory disease that typically becomes evident during early to mid-adulthood, as per NORD. It can also lead to the loss of spinal mobility for the affected individuals. The cause of the disease is not known, however, the HLA-B27 gene plays a major role. Ankylosing spondylitis is hereditary in nature.

TechNavio's analysts forecast the Global Ankylosing Spondylitis market to grow at a CAGR of 5.05 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Ankylosing Spondylitis market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of ankylosing spondylitis. The market is segmented based on the mechanism of action of the drugs used to treat ankylosing spondylitis as illustrated below:

  • TNF Inhibitors
  • COX Inhibitors
  • Others
  • On the type of molecule used for the treatment of ankylosing spondylitis, as illustrated below:
  • Biologics
  • Small Molecules
  • On the basis of route of administration adopted for the treatment of ankylosing spondylitis, the Global Ankylosing Spondylitis market is segmented as follows:
  • Oral
  • Parenteral
  • In addition, the market is also bifurcated on the basis of dosage forms of the drugs used in the treatment of the disease:
  • Solid
  • Liquid
  • The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market and also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. Also, the late-stage pipeline molecules developed for the treatment of Ankylosing Spondylitis have been discussed.

    TechNavio's report, Global Ankylosing Spondylitis Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC region and the EMEA; it also covers the Global Ankylosing Spondylitis market landscape and its growth prospects in the coming years. The report also includes a discussion on the key vendors operating in this market.

    Key Regions
    • Americas
    • APAC
    • EMEA
    Key Vendors
    • Abbvie
    • Amgen
    • Janssen Pharmaceuticals
    • Merck & Co.
    • Pfizer
    Other Prominent Vendors
    • Boehringer Ingelheim
    • Bristol-Myers Squibb
    • Celgene
    • Celltrion
    • Eisai
    • F. Hoffmann-La Roche
    • Merck Sharp & Dohme
    • Novartis
    • Otsuka Pharmaceutical
    • Regeneron Pharmaceuticals
    • Sanofi
    • Shanghai Pharmaceuticals
    • UCB
    Market Driver
    • Presence of Unmet Need
    • For a full, detailed list, view our report
    Market Challenge
    • Threat from Patent Expiry
    • For a full, detailed list, view our report
    Market Trend
    • Market Dominance by Biologics
    • For a full, detailed list, view our report
    Key Questions Answered in this Report
    • What will the market size be in 2019 and what will the growth rate be?
    • What are the key market trends?
    • What is driving this market?
    • What are the challenges to market growth?
    • Who are the key vendors in this market space?
    • What are the market opportunities and threats faced by the key vendors?
    • What are the strengths and weaknesses of the key vendors?


    Press Release

    TechNavio Announces the Publication of its Research Report – Global Ankylosing Spondylitis Market 2015-2019

    TechNavio recognizes the following companies as the key players in the Global Ankylosing Spondylitis Market: Abbvie Inc., Amgen Inc., Janssen Pharmaceuticals Inc., Merck & Co. Inc. and Pfizer Inc.

    Other Prominent Vendors in the market are: Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Eisai, F. Hoffmann-La Roche, Merck Sharp & Dohme, Novartis, Otsuka Pharmaceutical, Regeneron Pharmaceuticals, Sanofi, Shanghai Pharmaceuticals and UCB.

    Commenting on the report, an analyst from TechNavio’s team said: “The dominance of the market by biologics for the treatment of patients suffering from ankylosing spondylitis is one key trend in the market. Biologics are expected to be a preferred treatment option among the medical fraternity, patients, and the families of patients during the forecast period. This increases the number of treatment-seeking patients, which increases the overall consumption of medicines.”

    According to the report, presence of high unmet needs in terms of appropriate drugs is one of the major factors propelling the growth of the market. Current treatment options cannot cure the disease completely, and the drugs have a low safety profile, resulting in a rate high mortality. Therefore, drugs that can cause disease remission in patients and have a high safety profile are expected to drive the growth of the market.

    Further, the report states that expiry of patents is one of the major challenges hindering the growth of the market. Loss of patents of major drugs used in treatment of ankylosing spondylitis is expected to lower their revenue share, leading to a decrease in the overall revenue of the vendors in the market.Abbvie , Amgen , Janssen Pharmaceuticals , Merck & Co. , Pfizer , Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Eisai, F. Hoffmann-La Roche, Merck Sharp & Dohme, Novartis, Otsuka Pharmaceutical, Regeneron Pharmaceuticals, Sanofi, ShanghaiPharmaceuticals, UCB

    • Executive Summary
    • List of Abbreviations
    • Scope of the Report
      • Market Overview
      • Product Offerings
    • Market Research Methodology
      • Market Research Process
      • Research Methodology
        • Table Market Research Methodology
    • Introduction
      • Table Executive Summary of Global Ankylosing Spondylitis Market 2014-2019
    • Disease Overview
      • Understanding the Disease
        • Table Snapshot of Ankylosing Spondylitis
      • Causes of Ankylosing Spondylitis
      • Pathophysiology
      • Epidemiology
      • Diagnosis
        • Table Diagnosis of Ankylosing Spondylitis
      • Treatment and Management
        • Table Treatment and Management of Ankylosing Spondylitis
        • Analgesics
        • Corticosteroids
        • DMARDs
        • Biologics
        • Physiotherapy
        • Surgery
      • Economic Burden
        • Table Snapshot of Economic Burden of Ankylosing Spondylitis
    • Market Landscape
      • Market Overview
        • Table Snapshot of Global Ankylosing Spondylitis Market
      • Market Size and Forecast
        • Table Global Ankylosing Spondylitis Market 2014-2019 (US$ million)
        • Table Challenges and Drivers of Global Ankylosing Spondylitis Market
      • Five Forces Analysis
    • Market Segmentation by Mechanism of Action
      • Table Segmentation of Global Ankylosing Spondylitis Market by Mechanism of Action
      • TNF Inhibitors
      • COX Inhibitors
      • Others
        • Table Segmentation of Global Ankylosing Spondylitis Market by Mechanism of Action 2014
    • Market Segmentation by Type of Molecule
      • Table Segmentation of Global Ankylosing Spondylitis Market by Type of Molecule
      • Biologics
      • Small Molecules
        • Table Segmentation of Global Ankylosing Spondylitis Market by Type of Molecule 2014
    • Market Segmentation by Route of
      • Table Segmentation of Global Ankylosing Spondylitis Market by Route of Administration
      • Oral
      • Parenteral
        • Table Segmentation of Global Ankylosing Spondylitis Market by Route of Administration 2014
    • Market Segmentation by Dosage Form
      • Table Segmentation of Global Ankylosing Spondylitis Market by Dosage Form
      • Solid
      • Liquid
        • Table Segmentation of Global Ankylosing Spondylitis Market by Dosage Form 2014
    • Geographical Segmentation
      • Table Geographical Segmentation of Global Ankylosing Spondylitis Market 2014
    • Buying Criteria
      • Table Buying Criteria of Global Ankylosing Spondylitis Market
    • Market Growth Drivers
      • Table Growth Drivers of Global Ankylosing Spondylitis Market
    • Drivers and their Impact
      • Table Drivers and their Impact in Global Ankylosing Spondylitis Market by Key Customer Category
      • Table Drivers and their Impact in Global Ankylosing Spondylitis Market by Geography
    • Market Challenges
      • Table Challenges in Global Ankylosing Spondylitis Market
    • Impact of Drivers and Challenges
    • Market Trends
      • Table Trends in Global Ankylosing Spondylitis Market
    • Trends and their Impact
    • Vendor Landscape
      • Competitive Scenario
        • Key News
        • Mergers and Acquisitions
      • Market Share Analysis 2014
        • Table Global Ankylosing Spondylitis Market Share Analysis 2014
        • Competitive Assessment of Top Drugs for Ankylosing Spondylitis
          • Table YoY Revenue Comparison of Top Drugs for Ankylosing Spondylitis 2010-2013 (US$ million)
          • Table Revenue Share of Top Drugs for Ankylosing Spondylitis 2010-2013
        • AbbVie
          • Table Abbvie: Product Portfolio for Ankylosing Spondylitis
          • Table YoY Global Revenue of Humira 2008-2013 (US$ million)
        • Janssen Pharmaceuticals
          • Table Janssen: Product Portfolio for Ankylosing Spondylitis
          • Table YoY Revenue of Remicade 2005-2013 (US$ million)
          • Table YoY Revenue of Simponi 2010-2013 (US$ million)
        • Amgen
          • Table Amgen: Product Portfolio for Ankylosing Spondylitis
          • Table YoY Revenue of Enbrel in US and Canada 2005-2013 (US$ million)
          • Table YoY Revenue of Enbrel in US 2005-2013 (US$ million)
          • Table YoY Revenue of Enbrel In Canada 2005-2013 (US$ million)
          • Table Revenue Comparison of Enbrel by Region 2005-2013 (US$ million)
        • Pfizer
          • Table Pfizer: Product Portfolio for Ankylosing Spondylitis
          • Table YoY Revenue of Enbrel outside US and Canada 2009-2013 (US$ million)
          • Table YoY Revenue of Celebrex 2008-2013 (US$ million)
        • Merck
          • Table Merck: Product Portfolio for Ankylosing Spondylitis
          • Table YoY Revenue of Remicade 2009-2013 (US$ million)
          • Table YoY Revenue of Simponi 2010-2013 (US$ million)
      • Other and Future Prominent Vendors
    • Pipeline Portfolio
    • Key Vendor Analysis
      • AbbVie
        • Key Facts
        • Business Overview
        • Product Segmentation by Revenue 2013
          • Table AbbVie Inc.: Product Segmentation by Revenue 2013
        • Product Segmentation by Revenue 2012 and 2013
          • Table AbbVie Inc.: Product Segmentation by Revenue 2012 and 2013 (US$ million)
        • Sales by Geography
          • Table AbbVie Inc.: Sales by Geography 2013
        • Business Strategy
        • Key Developments
        • SWOT Analysis
      • Amgen
        • Key Facts
        • Business Overview
        • Business Segmentation by Revenue 2013
          • Table Amgen: Business Segmentation by Revenue 2013
        • Product Portfolio by Revenue 2013
          • Table Amgen: Product Portfolio by Revenue 2013
        • Business Segmentation by Revenue 2012 and 2013
          • Table Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
        • Geographical Segmentation by Revenue 2013
          • Table Amgen: Geographical Segmentation by Revenue 2013
        • Business Strategy
        • Recent Developments
        • SWOT Analysis
      • Janssen Pharmaceuticals
        • Key Facts
        • Business Overview
        • Recent Developments
        • SWOT Analysis
      • Merck
        • Key Facts
        • Business Overview
        • Business Segmentation by Revenue 2013
          • Table Merck & Co. Inc.: Business Segmentation by Revenue 2013
        • Business Segmentation by Revenue 2012 and 2013
          • Table Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
        • Sales by Geography
          • Table Merck & Co. Inc.: Sales by Geography 2013
        • Business Strategy
        • Key Developments
        • SWOT Analysis
      • Pfizer
        • Key Facts
        • Business Overview
        • Business Segmentation by Revenue 2013
          • Table Pfizer: Business Segmentation by Revenue 2013
        • Business Segmentation by Revenue 2012 and 2013
          • Table Pfizer: Business Segmentation by Revenue 2012 and 2013
        • Geographical Segmentation by Revenue
          • Table Pfizer: Geographical Segmentation by Revenue 2013
        • Business Strategy
        • Key Developments
        • SWOT Analysis
    • Other Reports in this Series

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report